...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of genetics >Effect of genetic and coexisting polymorphisms on platelet response to clopidogrel in Chinese Han patients with acute coronary syndrome
【24h】

Effect of genetic and coexisting polymorphisms on platelet response to clopidogrel in Chinese Han patients with acute coronary syndrome

机译：遗传和共存多态性对中国汉族急性冠脉综合征患者氯吡格雷反应的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Polymorphisms of CYP2C19 are associated with platelet response to clopidogrel. This study was conducted to evaluate the contribution of the previously identified polymorphisms to the response of clopidogrel in a cohort of Chinese Han patients. A total of 222 acute coronary syndrome patients undergoing percutaneous coronary intervention treated with clopidogrel were enrolled from September 2012 to June 2013. Residual platelet aggregations for all patients were measured by the VerifyNow P2Y12 system. Sixteen single-nucleotide polymorphisms among nine genes were genotyped including CYP2C19, ABCB1 and PON1. In this study, CYP2C19*2 and CYP2C19*17 were strongly associated with higher platelet aggregation and lower platelet aggregation to clopidogrel treatment, respectively (P < 0.001). Patients with CYP2C19*2 allele had a higher risk of high on-treatment platelet reactivity than non carriers (adjusted OR, 5.434; 95% CI, 1.918-15.399, P=0.01). The coexistence of CYP2B6*9 (rs8192719) and P2Y12 (rs2046934) and the coexistence of CYP2B6*1B (rs7254579) and P2Y12 (rs2046934) were also associated with poor response to clopidogrel. No significant relation of CYP2C19*3 and other polymorphisms to the platelet aggregation was found. In conclusion, CYP2C19*2, CYP2C19*17 coexistence of CYP2B6*9 (rs8192719) and P2Y12 (rs2046934) and coexistence of CYP2B6*1B (rs7254579) and P2Y12 (rs2046934) were identified to be associated with response to clopidogrel treatment in Chinese Han patients.
机译：CYP2C19的多态性与血小板对氯吡格雷的反应有关。进行这项研究以评估先前鉴定的多态性对中国汉族人群中氯吡格雷反应的影响。从2012年9月至2013年6月，共有222例接受氯吡格雷经皮冠状动脉介入治疗的急性冠状动脉综合征患者入组。所有患者的残余血小板聚集均通过VerifyNow P2Y12系统进行测量。对9个基因中的16个单核苷酸多态性进行了基因分型，包括CYP2C19，ABCB1和PON1。在这项研究中，CYP2C19 * 2和CYP2C19 * 17与氯吡格雷治疗分别与较高的血小板聚集和较低的血小板聚集密切相关（P <0.001）。 CYP2C19 * 2等位基因患者的治疗中血小板反应性高的危险性高于非携带者（校正后OR，5.434; 95％CI，1.918-15.399，P = 0.01）。 CYP2B6 * 9（rs8192719）和P2Y12（rs2046934）的共存以及CYP2B6 * 1B（rs7254579）和P2Y12（rs2046934）的共存也与对氯吡格雷的不良反应有关。没有发现CYP2C19 * 3和其他多态性与血小板聚集有显着关系。总之，在中国人中，CYP2B6 * 9（rs8192719）和P2Y12（rs2046934）以及CYP2B6 * 1B（rs7254579）和P2Y12（rs2046934）的CYP2C19 * 2，CYP2C19 * 17共存被确定与对氯吡格雷的治疗反应相关耐心。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号